| Literature DB >> 3300957 |
P J O'Dwyer, S A King, D F Hoth, B Leyland-Jones.
Abstract
The role of thymidine in the treatment of cancer has been under clinical investigation for nearly a decade. Clinical trials have demonstrated that it lacks antitumor activity in its own right. In this review, the mechanism of action and rationale for the use of thymidine as a biochemical modulator of standard agents such as 5-fluorouracil, 1-beta-D-arabinofuranosylcytosine, and methotrexate are summarized. With this background, the clinical trials which have been conducted with thymidine, either alone or in combination, are described. We suggest a number of further studies of the role of thymidine in the biochemical modulation of antimetabolites.Entities:
Mesh：
Substances：
Year: 1987 PMID： 3300957
Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701